Eurostars project E!11284 P-CALPRO, Getica AB. A new marker for differentiating between bacterial and viral infections
| Reference number | |
| Coordinator | GETICA AB - Sahlgrenska Science Park |
| Funding from Vinnova | SEK 3 384 248 |
| Project duration | September 2017 - March 2020 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
The Calrptectin has been assay and has been designed, verified and validated in peer reviewed journals and is demonstrated to be superior to procalcitonin, C-reactive protein as a sepsis marker and predictor of 30-day mortality in intensive care patients.
Expected long term effects
Objectives: To assess the value of plasma calprotectin as an early marker of bacterial infections in critically ill patients and compare it with the corresponding values for procalcitonin (PCT), C-reactive protein (CRP) and white blood cell count (WBC).
Approach and implementation
Planning the clinical studies was performed and kinetics of calprotectin was investigated in several studies and compared to kinetics of the established biomarkers. When neutrophils were exposed to either E. coli or endotoxin, calprotectin levels began to increase within a couple of hours after the challenge. Calprotectin peaked earlier than comparator soluble mediators (procalcitonin 8hrs, CRP, 24hrs) and exhibited 100% sensitivity. Given the logistic advantages with rapid turbidimetric assay, this is of interest in early diagnosis of bacterial infections.